Progyny, Inc. Accretion Expense
Progyny, Inc. (PGNY) reported Accretion Expense of $75.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2021-03-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2021-03-01
- Progyny, Inc. accretion expense for the quarter ending 2018-12-31 was $0.00.
- Progyny, Inc. accretion expense for fiscal 2018 was $75.00K, a 62.50% decline from fiscal 2017.
- Progyny, Inc. accretion expense for fiscal 2017 was $200.00K.
| Period end | Accretion Expense 3 month | Accretion Expense 9 month | Accretion Expense 12 month |
|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $75.00K 10-K · filed 2021-03-01 | |
| 2018-09-30 | $75.00K 10-Q · filed 2019-12-06 | ||
| 2017-12-31 | $200.00K 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |